Amygdala Neurosciences Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2M

  • Investors
  • 4

Amygdala Neurosciences General Information

Description

Developer of a biopharmaceutical technology intended to focus on the large and growing unmet need associated with substance use disorders. The company's technology uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated cravings without changes to basal dopamine, enabling patients to quit and get rid of their addiction to drugs, alcohol, and smoking.

Contact Information

Website
www.amygns.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 5214F Diamond Heights Boulevard
  • Suite 151
  • San Francisco, CA 94131
  • United States
+1 (650) 000-0000

Amygdala Neurosciences Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amygdala Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 01-Aug-2023 $2M 000.00 Completed Generating Revenue
7. Grant 10-Sep-2021 00.000 000.00 Completed Pre-Clinical Trials
6. Seed Round 28-Apr-2021 00.00 000.00 000.00 Completed Pre-Clinical Trials
5. Grant 21-Oct-2019 00.000 00.000 Completed Generating Revenue
4. Grant 19-Sep-2018 000.00 00.000 Completed Generating Revenue
3. Seed Round 19-May-2017 00.000 00.000 000.00 Completed Generating Revenue
2. Seed Round 10-Feb-2017 $2M $3.45M 000.00 Completed Generating Revenue
1. Seed Round 10-Apr-2015 $1.45M $1.45M 000 Completed Generating Revenue
To view Amygdala Neurosciences’s complete valuation and funding history, request access »

Amygdala Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-4 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed-3 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Seed-2 4,340,673 $0.000100 $0.03 $0.55 $0.55 1x $0.5 11.97%
Seed-1 5,307,464 $0.000100 $0.02 $0.27 $0.27 1x $0.27 13.24%
To view Amygdala Neurosciences’s complete cap table history, request access »

Amygdala Neurosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biopharmaceutical technology intended to focus on the large and growing unmet need associated with substa
Drug Discovery
San Francisco, CA
000.00
0000000000 000.00

000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolor
0000 000000000
New York, NY
00 As of 0000
00000
000000000 00000

000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000000000000
South San Francisco, CA
00 As of 0000
00000
00000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amygdala Neurosciences Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurogene Formerly VC-backed New York, NY 00 00000 000000000 00000
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
T3D Therapeutics Venture Capital-Backed Durham, NC 00 000.00 00000000000 000.00
Alkahest Formerly VC-backed San Carlos, CA 00 000.00 000000&0 000.00
Cerecin Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
You’re viewing 5 of 43 competitors. Get the full list »

Amygdala Neurosciences Executive Team (6)

Name Title Board Seat Contact Info
Brent Blackburn Ph.D Co-Founder & Chief Executive Officer
Adrienne MacMillan Co-Founder, Chief Financial Officer & Board Member
Ivan Diamond Ph.D Co-Founder & Chief Scientific Officer
Louis Lange MD Co-Founder & Executive Chairman
Peter Strumph Co-Founder & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Amygdala Neurosciences Board Members (5)

Name Representing Role Since
Adrienne MacMillan Amygdala Neurosciences Co-Founder, Chief Financial Officer & Board Member 000 0000
Howard Jaffe MD Amygdala Neurosciences Board Member 000 0000
Louis Lange MD Amygdala Neurosciences Co-Founder & Executive Chairman 000 0000
Peter Strumph Amygdala Neurosciences Co-Founder & Board Member 000 0000
William Lee Ph.D Self Board Member 000 0000
To view Amygdala Neurosciences’s complete board members history, request access »

Amygdala Neurosciences Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Altamont Pharmaceutical Holdings Holding Company Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
National Institute of Alcohol Abuse and Alcoholism Government 000 0000 000000 0
To view Amygdala Neurosciences’s complete investors history, request access »

Amygdala Neurosciences Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gilead Sciences (GS-6637) 16-Feb-2017 000000000 Buildings and Property 00000 000
To view Amygdala Neurosciences’s complete investments history, request access »

Amygdala Neurosciences FAQs

  • When was Amygdala Neurosciences founded?

    Amygdala Neurosciences was founded in 2015.

  • Who is the founder of Amygdala Neurosciences?

    Brent Blackburn Ph.D, Adrienne MacMillan, Ivan Diamond Ph.D, Louis Lange MD, and Peter Strumph are the founders of Amygdala Neurosciences.

  • Who is the CEO of Amygdala Neurosciences?

    Brent Blackburn Ph.D is the CEO of Amygdala Neurosciences.

  • Where is Amygdala Neurosciences headquartered?

    Amygdala Neurosciences is headquartered in San Francisco, CA.

  • What industry is Amygdala Neurosciences in?

    Amygdala Neurosciences’s primary industry is Drug Discovery.

  • Is Amygdala Neurosciences a private or public company?

    Amygdala Neurosciences is a Private company.

  • What is Amygdala Neurosciences’s current revenue?

    The current revenue for Amygdala Neurosciences is 000000.

  • How much funding has Amygdala Neurosciences raised over time?

    Amygdala Neurosciences has raised $10.1M.

  • Who are Amygdala Neurosciences’s investors?

    National Institutes of Health, Altamont Pharmaceutical Holdings, Asset Management Ventures, and National Institute of Alcohol Abuse and Alcoholism have invested in Amygdala Neurosciences.

  • Who are Amygdala Neurosciences’s competitors?

    Neurogene, Neurona Therapeutics, T3D Therapeutics, Alkahest, and Cerecin are some of the 43 competitors of Amygdala Neurosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »